Chronic Pain Market Report 2026

The chronic pain market size has grown strongly in recent years. It will grow from $84.66 billion in 2025 to $91.67 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases, rising incidence of neuropathic and musculoskeletal pain, wider availability of pain medications, growing clinical recognition of chronic pain, expansion of pain clinics.

The chronic pain market size is expected to see strong growth in the next few years. It will grow to $127.4 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing demand for personalized pain therapies, rising adoption of bioelectronic devices, expansion of telehealth-based pain care, growing focus on opioid alternatives, increased investment in pain research. Major trends in the forecast period include increasing adoption of multidisciplinary pain care models, rising use of neuromodulation devices, growing preference for non-opioid drug therapies, expansion of home-based pain management solutions, enhanced integration of digital health platforms.

The prevalence of chronic pain patients is anticipated to drive the growth of the chronic pain market. Chronic pain patients are individuals who experience persistent or long-term pain that extends beyond the normal healing period or continues for an extended duration, typically longer than three months. The high prevalence of chronic pain increases demand for effective pain management solutions, including pharmaceuticals and medical devices, thereby creating opportunities for innovation and development within the market. For example, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, approximately 4 million Australians, representing 16% of the population, were living with back problems in 2022. By 2023, back problems became the third leading cause of disease burden, accounting for 4.3% of the total disease burden in the country. Additionally, in February 2024, according to a report published by the Institute for Health Metrics and Evaluation, a US-based public health research organization, global cases of neck pain are projected to reach 269 million by 2050, with estimates ranging from 219 to 322 million. Therefore, the growing prevalence of chronic pain patients is contributing to the expansion of the chronic pain market.

Major companies operating in the chronic pain market are increasingly adopting strategic partnership approaches to introduce shared savings programs for chronic pain management. Strategic partnerships involve companies combining their strengths and resources to achieve shared objectives and mutual success. For instance, in August 2023, MOBĒ, a US-based digital health innovator, partnered with Override Health, a US-based healthcare company, to improve chronic pain management through a shared savings program that integrates their respective expertise. MOBĒ, as a health outcomes-focused organization, uses healthcare data analytics to support its personalized, high-touch health coaching and medication management model. In contrast, Override Health provides an integrated program that includes virtual interdisciplinary care, neuroplasticity-focused coaching, and peer support to help individuals with chronic pain navigate fragmented care pathways.

In October 2024, Stryker Corporation, a US-based medical technology company, acquired Vertos Medical Inc. for an undisclosed amount. This acquisition was intended to strengthen Stryker’s portfolio of unique, non-surgical solutions for interventional specialists treating chronic lower back pain, while also expanding its presence in ambulatory surgery centers. Vertos Medical Inc. is a US-based manufacturer of chronic pain management devices, with a particular focus on treatments for chronic lower back pain associated with lumbar spinal stenosis.

Major companies operating in the chronic pain market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, Mitsubishi Chemical Group Corporation, GlaxoSmithKline plc., Eli Lilly and Company, AstraZeneca plc., Becton, Dickinson, and Company, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Endo International plc., Noven Pharmaceuticals Inc., Anika Therapeutics Inc., Collegium Pharmaceutical Inc., Heron Therapeutics Inc., Paradigm Biopharmaceuticals Ltd., Braeburn Inc., Taiwan Liposome Company Ltd., Axial Healthcare, AcelRx Pharmaceuticals Inc., Centrexion Therapeutics Corp., Vertanical GmbH, IKI Health Group, Tonix Pharmaceuticals Inc., Paperplane Therapeutics.

North America was the largest region in the chronic pain market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pain market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the chronic pain market by raising costs of imported medical devices, neurostimulation systems, pharmaceutical ingredients, and digital health technologies used across pain treatment settings. Hospitals and clinics in North America and Europe are most affected due to reliance on imported devices and specialty drugs, while Asia-Pacific faces cost pressures in manufacturing and distribution. These tariffs are increasing treatment expenses and slowing adoption of advanced pain technologies. However, they are also promoting domestic device manufacturing, local drug production, and innovation in cost-efficient pain management solutions.

The chronic pain market research report is one of a series of new reports that provides chronic pain market statistics, including chronic pain industry global market size, regional shares, competitors with a chronic pain market share, detailed chronic pain market segments, market trends and opportunities, and any further data you may need to thrive in the chronic pain industry. This chronic pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic pain is defined as persistent or long-term pain that continues beyond the typical healing period of an injury or illness. It can arise from a wide range of causes, including injuries, underlying medical conditions, nerve damage, inflammation, musculoskeletal disorders, and certain diseases such as arthritis, fibromyalgia, or neuropathy.

The primary products used in chronic pain management include drugs and devices. A drug is a substance used to diagnose, prevent, or treat a disease or medical condition. Medications such as opioids and non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed to relieve pain symptoms and address underlying causes. These products are used for multiple indications, including neuropathic pain, arthritis pain, chronic back pain, cancer pain, migraine, fibromyalgia, and others, across various end users such as hospitals, clinics, and research organizations.

The chronic pain market consists of sales of opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants, and other analgesics that are used to manage chronic pain. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.